Table 4. Summary of MMA results by site and fusion transcript.
| Site 1 | Site 2 | Site 3 | Site 4 | Total | Agreement (%) | |
|---|---|---|---|---|---|---|
| BCR–ABL1 e13a2 | 7 | 6 | 3 | 3 | 19 | 100 |
| BCR–ABL1 e14a2 | 3 | 6 | 5 | 2 | 16 | 99.6a |
| BCR–ABL1 e1a2 | 7 | 6 | 3 | 2 | 18 | 99.6a |
| ETV6–RUNX1 | 0 | 5 | 4 | 0 | 9 | 100 |
| MLL–AFF1 | 0 | 8 | 6 | 0 | 14 | 99.3b |
| CBFB–MYH11 A | 4 | 6 | 5 | 2 | 17 | 100 |
| CBFB–MYH11 D | 0 | 1 | 0 | 1 | 2 | 100 |
| PML–RARA bcr 1 | 2 | 5 | 3 | 0 | 10 | 100 |
| PML–RARA bcr 3 | 7 | 5 | 4 | 0 | 16 | 100 |
| RUNX1–RUNX1T1 | 2 | 6 | 4 | 4 | 16 | 100 |
| TCF3–PBX1 | 0 | 5 | 3 | 0 | 8 | 100 |
| Positive | 32 | 59 | 40 | 14 | 145 | |
| Negative | 37 | 12 | 42 | 44 | 135 | |
| Fail | 0 | 1 | 0 | 0 | 1 | |
| Total | 69 | 72 | 82 | 58 | 281 | |
| Overall agreement | 97.1%a | 100% | 97.6%b | 100% |
Abbreviation: MMA, multiplex molecular assay.
a
One CML and one ALL t(9;22) positive cases in cytogenetic remission at follow-up were positive at site 1.
b
Two ALL t(4;11) positive cases at presentation were negative at site 3.